NurExone Announces Q4 and Full-year 2022 Financial Results and Provides Company Update, Highlighting 143.9% Scientific Research Investment Growth
TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the…
TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the…
TORONTO and TEL AVIV, Israel, March 30, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the…
This year’s award is successive to last year’s recognition as NewBeauty’s winner for “Best in…
This year’s award is successive to last year’s recognition as NewBeauty’s winner for “Best in…
— Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series…
— Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series…
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on…
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on…
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”)…
PHOENIX, March 30, 2023 (GLOBE NEWSWIRE) — MedAvail Holdings, Inc. (NASDAQ: MDVL) (“MedAvail” or the…
PHOENIX, March 30, 2023 (GLOBE NEWSWIRE) — MedAvail Holdings, Inc. (NASDAQ: MDVL) (“MedAvail” or the…
Daix (France), Long Island City (New York, United States), March 30, 2023 Inventiva (Euronext Paris…
Daix (France), Long Island City (New York, United States), March 30, 2023 Inventiva (Euronext Paris…
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE…
NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) — Rumi Scientific (“Rumi”), a developer of therapies…
SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences,…
DataStax Honored with Six New Workplace Awards from Comparably: Best Company Outlook, Best Company to…
– Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered…
Company has completed Phase 3 manufacturing of PDS0101 for randomized, controlled, registrational trial in recurrent/metastatic…